Navigation Links
Questcor Adds G. Kelly Martin to Board of Directors
Date:11/12/2013

Questcor has announced its intent to initiate a pilot commercialization effort for Acthar for the treatment of respiratory manifestations of symptomatic sarcoidosis. The FDA approved package insert for Acthar includes "symptomatic sarcoidosis" under the heading "Respiratory Diseases."  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. Questcor also has agreed to acquire certain international rights for Synacthen® (tetracosactide) and Synacthen Depot®, and has licensed the right to develop and seek FDA approval for these products in the United States. For more information about Questcor, please visit www.questcor.com

Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "believes," "continue," "could," "ensuring," "estimates," "expects," "growth," "may," "momentum," "plans," "potential," "remain," "should," "start," "substantial," "sustainable" or "will" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:

  • Our reliance on Acthar for substantially all of our net sales and profits;
  • Our ability to continue to generate revenue from sales of Acthar to treat on-label indications associated with NS, MS, IS or rheumatology-rel
    '/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
2. Questcor to Report Second Quarter Results on July 24, 2012
3. Questcor Reports Second Quarter Financial Results
4. Questcor Pharmaceuticals to Present at Investor Conferences in September
5. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
6. Questcor Comments on Insurance Policy Bulletin
7. Questcor to Conduct Conference Call to Discuss Reimbursement Process
8. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
9. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
10. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
11. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  Depomed, Inc. (NASDAQ: ... second quarter fiscal year 2014 financial results after the ... host a conference call beginning at 4:30 pm EDT, 1:30 ... access the call by dialing 877-317-6789 ( United ... will also be available via a live webcast on ...
(Date:7/25/2014)... July 25, 2014 GrowBLOX Sciences, Inc. (OTCQB: GBLX) ... of Understanding ("MOU") with LaurelCo, LLC, an Illinois ... of both cultivation and dispensary medical marijuana licenses in the ... MOU, GBLX will acquire a 20% equity interest in LaurelCo, ... TM growing chambers, as well as all technology related ...
(Date:7/25/2014)... July 25, 2014 According to ... "Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, ... Share, Growth, Trends and Forecast (Value and Volume), 2013 ... USD 19.99 billion in 2012 and is expected to ... 2019 to reach USD 32.24 billion in 2019. ...
Breaking Medicine Technology:Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
... Helen Londe, M.D. Contributing Editor The first human case of ... occurred in Kansas in late June. The CDC has ... being 2005's first documented incidence of the mosquito borne disease ... about 11 kb. It primarily infects birds and mosquitoes, ...
... lipids, comprised of triglycerides and cholesterols, vary with genetic ... factors contribute to serum cholesterol and triglyceride levels and ... events. Perhaps no other commonly determined medical laboratory values ... levels of good, bad, and total cholesterol, making the ...
Cached Medicine Technology:West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak 2West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak 3West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak 4Analyzers Offer Point-of-Care Lipid Panels 2Analyzers Offer Point-of-Care Lipid Panels 3
(Date:7/28/2014)... (PRWEB) July 28, 2014 As health ... are looking to private exchanges. “Private Exchange Strategies ... 6 webinar from Atlantic Information Services, will provide answers ... exchange strategies for the future. , Barbara Gniewek, Jonathan ... with extensive experience in the private exchange sector — ...
(Date:7/28/2014)... According to the Heartburn No More PDF review recently ... help people get rid of acid reflux naturally. ... heartburn and acid reflux. In addition, inside this book, people ... factors for reflux disease. , Vkool informs in its ... symptoms of reflux disease naturally without medications. The book also ...
(Date:7/28/2014)... 28, 2014 Building a sense of ... important. Where personal outdoor space is not possible, ... enjoy fun and exercise outside is important. That’s ... in quality commercial playground equipment from APCPLAY. , Old ... Midlothian, Virginia. It is an historic tourist location of ...
(Date:7/28/2014)... Calif., July 27, 2014 - (PRWEB) July 28, 2014 ... in 12 months by earning the Masters Champion title at ... proving that age is no obstacle for this athlete. She ... at the event hosted by the International Pole Sports Federation ... 63, traveling from 30 countries, took part in the competition. ...
(Date:7/28/2014)... Dr. Alan Xenakis, MD announced today the ... Feelings.” The new book, DOC X MD Funny Feelings ... story telling style with humor and medical accuracy. The book ... will find answers to those age-old questions that most folks ... pee? Why do mosquitoes bite some and not others? Why ...
Breaking Medicine News(10 mins):Health News:Three PwC Consultants to Offer Insurers Successful Strategies for Private Exchanges 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Playground Creates Outdoor Fun for Community at Old Buckingham Station at Midlothian Village (VA) with APCPLAY© 2Health News:Inspiring Senior Athlete Lands Third World Title in One Year 2Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2
... Texas Pesticides and pollutants are related to an alarming ... anencephaly in rural China, according to scientists at The University ... of the pesticides found in high concentrations in the placentas ... Endosulfan is only now being phased out in the United ...
... Steven Reinberg HealthDay Reporter , TUESDAY, Oct. ... friends tend to have areas of the brain that ... with fewer friends, British researchers say. "We were ... in them is reflected in brain structure and function," ...
... cardiac arrest is the leading cause of death in the ... initial collapse. In addition, fewer than half of the small ... the hospital, because they often suffer irreversible brain damage. A ... Neurology provides guidance to physicians using therapeutic cooling to ...
... flushes and night sweats years after the menopause finds a new ... and Gynaecology . Hot flushes and night sweats (HF/NS) are ... severity and duration vary considerably. The average age of ... it is generally assumed that HF/NS last between 2 to 5 ...
... Spanish . Researchers from Massachusetts General ... cell mechanism activated by a protein HOXB9 that becomes an ... world continue to focus their research on breast cancer. As ... growing, as well as of their interactions with the microenvironment. ...
... Duke University Medical Center researchers have verified data that ... a patient who has been under anesthesia for an operation. ... first year after surgery if a patient has low values ... patients whose values are all normal. The three ...
Cached Medicine News:Health News:Study links pollutants to a 450 percent increase in risk of birth defects 2Health News:Study links pollutants to a 450 percent increase in risk of birth defects 3Health News:More Facebook Friends, More Gray Matter in Brain? 2Health News:More Facebook Friends, More Gray Matter in Brain? 3Health News:Mayo Clinic study guides physicians using therapeutic cooling to treat cardiac arrest patients 2Health News:Older women still suffer from hot flushes and night sweats years after the menopause finds study 2Health News:Discovery of a cell mechanism that reduces effectiveness of breast cancer treatment 2Health News:3 factors could point to your fate after surgery 2
... The proper gel is essential ... when working with pH catheters ... specific chloride ion concentration in ... required for proper function of ...
The WaveMax is one of the most flexible stainless steel stents due to its unique wave design and has the lowest effective profile, accommodating a 6F sheath up to 7 mm....
... its specifically designed reagents, allows to ... sample, multiple analytes. This unique technology ... laboratories willing to simplify and standardize ... as well as to reduce as ...
... a variety of applications across a broad ... is suitable for any laboratory demanding high ... mixed-mode throughput exceeding 95 PT/aPTT/Fibrinogen per hour ... range of chromogenics, the AMAX DestinyPlus is ...
Medicine Products: